What is Enhertu, and how does it work?

Enhertu is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received two or more prior anti-HER2 breast cancer treatments.

It is not known if Enhertu is safe and effective in children.

What are the side effects of Enhertu?

WARNING

INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY

  • Interstitial Lung Disease (ILD) and pneumonitis, including fatal cases, have been reported with Enhertu.Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new orworsening respiratory symptoms. Permanently discontinue Enhertu in all patients with Grade 2 or higherILD/pneumonitis. Advise patients of the risk and the need to immediately report symptoms.
  • Embryo-Fetal Toxicity: Exposure to Enhertu during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.

Enhertu can cause serious side effects.

The most common side effects of Enhertu include:

Enhertu may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of Enhertu. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is the dosage for Enhertu?

Recommended Dosage And Schedules

Do Not Substitute Enhertu For Or With Trastuzumab Or Ado-Trastuzumab Emtansine
  • The recommended dosage of Enhertu is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
First Infusion
  • Administer infusion over 90 minutes.
Subsequent Infusions
  • Administer over 30 minutes if prior infusions were well tolerated.
  • Slow or interrupt the infusion rate if the patient develops infusion-related symptoms.
  • Permanently discontinue Enhertu in case of severe infusion reactions.

Dose Modifications

  • Management of adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of Enhertu as described in Tables 1 and 2.
Do Not Re-Escalate The Enhertu Dose After A Dose Reduction Is Made
  • If a planned dose is delayed or missed, administer as soon as possible; do not wait until the next planned cycle.
  • Adjust the schedule of administration to maintain a 3-week interval between doses. Administer the infusion at the dose and rate the patient tolerated in the most recent infusion.

Table 1: Dose Reduction Schedule

Dose Reduction Schedule
(Starting dose is 5.4 mg/kg.)
Dose to be administered
First dose reduction4.4 mg/kg
Second dose reduction3.2 mg/kg
Requirement for further dose reductionDiscontinue treatment

Table 2: Dose Modifications for Adverse Reactions

Adverse ReactionSeverityTreatment Modification
Interstitial Lung Disease (ILD)/pneumonitisAsymptomatic ILD/pneumonitis (Grade 1)Interrupt Enhertu until resolved to Grade 0, then:
  • if resolved in 28 days or less from date of onset, maintain dose.
  • if resolved in greater than 28 days from date of onset, reduce dose one level (see Table 1).
  • consider corticosteroid treatment as soon as ILD/pneumonitis is suspected.
Symptomatic ILD/pneumonitis (Grade 2 or greater)
  • Permanently discontinue Enhertu.
  • Promptly initiate corticosteroid treatment as soon as ILD/pneumonitis is suspected.
NeutropeniaGrade 3 (less than 1.0 to 0.5 x 109/L)
  • Interrupt Enhertu until resolved to Grade 2 or less, then maintain dose.
Grade 4 (less than 0.5 x 109/L)
  • Interrupt Enhertu until resolved to Grade 2 or less.
  • Reduce dose by one level (see Table 1).
Febrile NeutropeniaAbsolute neutrophil count of less than 1.0 x 109/L and temperature greater than 38.3°C or a sustained temperature of 38°C or greater for more than one hour
  • Interrupt Enhertu until resolved.
  • Reduce dose by one level (see Table 1).
Left Ventricular DysfunctionLVEF greater than 45% and absolute decrease from baseline is 10% to 20%
  • Continue treatment with Enhertu.
LVEF 40% to 45%And absolute decrease from baseline is less than 10%
  • Continue treatment with Enhertu.
  • Repeat LVEF assessment within 3 weeks.
And absolute decrease from baseline is 10% to 20%
  • Interrupt Enhertu.
  • Repeat LVEF assessment within 3 weeks.
  • If LVEF has not recovered to within 10% from baseline, permanently discontinue Enhertu.
  • If LVEF recovers to within 10% from baseline, resume treatment with Enhertu at the same dose.
LVEF less than 40% or absolute decrease from baseline is greater than 20%
  • Interrupt Enhertu.
  • Repeat LVEF assessment within 3 weeks.
  • If LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed, permanently discontinue Enhertu.
Symptomatic congestive heart failure (CHF)
  • Permanently discontinue Enhertu.
Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v.4.03).

SLIDESHOW

Breast Cancer Awareness: Symptoms, Diagnosis, and Treatment See Slideshow

What drugs interact with Enhertu?

No Information Provided

Is Enhertu safe to use while pregnant or breastfeeding?

  • Based on its mechanism of action, Enhertu can cause fetal harm when administered to a pregnant woman.
  • There are no available data on the use of Enhertu in pregnant women.
  • In postmarketing reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death.
  • There is no data regarding the presence of fam-trastuzumab deruxtecan-nxki in human milk, the effects on the breastfed child, or the effects on milk production.
  • Because of the potential for serious adverse reactions in a breastfed child, women should not breastfeed during treatment with Enhertu and for 7 months after the last dose.

Summary

Enhertu is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received two or more prior anti-HER2 breast cancer treatments. Serious side effects of Enhertu include interstitial lung Disease (ILD) and pneumonitis including fatal cases), and embryo-fetal toxicity.

Treatment & Diagnosis

Medications & Supplements

QUESTION

A lump in the breast is almost always cancer. See Answer

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 11/9/2020
References
All sections courtesy of the U.S. Food and Drug Administration